TD Cowen Raises REGN Price Target to $980
Key Points
- TD Cowen reiterated its Buy rating on Regeneron Pharmaceuticals, Inc. on October 21, 2026, raising its price target to $980 from $960.
- TD Cowen's $980 price target implies 21.37% upside from Regeneron Pharmaceuticals, Inc.'s ($REGN) current $807.48 share price.
- Regeneron recently traded around $807.48 on October 21, 2026, closing that day at $805.02.
- The company reported trailing twelve-month revenue of $15.53 billion alongside earnings of $40.44 per share.
Get Regeneron Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $REGN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Regeneron Pharmaceuticals, Inc. alert may contain errors. Disclosures
TD Cowen reiterated its Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on October 21, 2026, while raising its price target from $960.00 to $980.00. The research note arrived as shares traded near the upper end of their 52-week range, prompting a look at how the new target stacks up against the broader biotech sector. Regeneron closed at $805.02 on October 21, 2026, and recently traded around $807.48. That puts the stock roughly 6.0% below its 52-week high of $859.34 and about 41.0% above its 52-week low of $572.75. The shares also sit above both their 50-day moving average of $790.80 and their 200-day moving average of $735.62.
REGN
Regeneron Pharmaceuticals, Inc.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Regeneron Pharmaceuticals, Inc.
Large institutional funds have adjusted their positions in the biotech firm over recent reporting periods. Dodge & Cox Inc. grew its holdings by 412,838 shares, ending with 4,871,137 shares worth about $3,921,362,802.00. Franklin Resources, Inc. added 49,813 shares for a 1.8% increase, finishing with 2,771,839 shares valued at approximately $2,231,385,885.00. Nuveen, LLC trimmed its stake by reducing holdings by 45,017 shares, leaving it with 2,019,974 shares worth roughly $1,626,119,508.00 after a 2.2% decrease.
Regeneron Pharmaceuticals, Inc. Stock Holds Steady
Regeneron carries a market capitalization of $82.88 billion and a price-to-earnings ratio of 19.91. The stock trades with a low beta of 0.15, pointing to lower volatility than the broader market. The current price sits about 6.6% below the consensus analyst mean price target of $864.74, and about 17.6% below TD Cowen's fresh $980 target.
$REGN price target
Regeneron Pharmaceuticals, Inc. daily closes and this analyst's $980 target. Not advice.
Recent Earnings
Regeneron pulled in trailing-twelve-month revenue of $15.53 billion with earnings of $40.44 per share. The company posted a net profit margin of 27.9% and a return on equity of 14.0%, while revenue grew 16.7% year-over-year. Investors can look toward the next earnings release scheduled for October 30, 2026.
Dividend
Regeneron pays an annual dividend rate of $3.76 per share, giving it a dividend yield of 0.47%. The payout ratio sits at 9.0% of earnings.
Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.
Company insiders have completed several transactions in recent months. Director Kathryn Ph.D. Guarini sold 400 shares on August 10, 2026, at a price of $800.00, totaling $320,000.00. Director Huda Y Zoghbi sold 800 shares on August 10, 2026, at $800.00 per share for a total value of $640,000.00. Later, on September 2, 2026, Kathryn Ph.D. Guarini sold another 400 shares at $850.00 per share, netting $340,000.00. Officer Marion E Mccourt disposed of 2,346 shares on September 3, 2026, with a total value of $2,002,458.00.
Analysts Set New Price Targets
Wall Street firms continue to update their outlooks on the drug developer. Truist Securities maintained its Buy rating on October 7, 2026, lifting its target from $772.00 to $780.00. RBC Capital maintained a Sector Perform rating on October 8, 2026, raising its target from $737.00 to $810.00. UBS upgraded the stock to a Buy on October 15, 2026, substantially lifting its target from $660.00 to $978.00. Piper Sandler maintained an Overweight rating on October 19, 2026, pushing its target from $854.00 to $865.00. Overall, the stock holds a consensus buy recommendation across 27 analyst opinions.
About Regeneron Pharmaceuticals, Inc.
Headquartered in Tarrytown, New York, Regeneron Pharmaceuticals discovers and develops specialized medicines for serious medical conditions. The firm focuses on treatments for eye diseases, inflammatory conditions, cardiovascular issues, metabolic disorders, cancer, and rare diseases. Its research pipeline aims to bring novel biologic therapies to patients worldwide.
Bottom Line
TD Cowen's target increase to $980 comes just ahead of Regeneron's upcoming earnings report on October 30, 2026. Investors will be watching the upcoming financial results to see if revenue growth and profit margins support these higher Wall Street expectations.
Related Filing Alerts
Source: TD Cowen's rating change on $REGN (Oct 21, 2026). Written by software, not financial advice. How we make alerts